<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Calpain is a calcium-dependent cysteine protease that is implicated in calcium-dependent cell <z:hpo ids='HP_0011420'>death</z:hpo>, and calpain inhibitors are generally considered as inhibitors of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>To the contrary, in the present study, we found that calpain inhibitor II (CPI-2) triggers rapid <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) and non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) cells </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> target cell lines were killed by CPI-2, including: ALL-1, a multidrug-resistant BCR-ABL fusion transcript-positive t(9;22) <z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">pro-B ALL</z:e> cell line; RS4;11, a highly radiation-resistant MLL-AF4 fusion transcript-positive t(4;11) <z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">pre-pre B ALL</z:e> cell line; RAMOS, a highly radiation-resistant and p53-deficient Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell line; DAUDI, a Burkitt's <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell line; NALM-6, a <z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">pre-B ALL</z:e> cell line; and JURKAT and MOLT-3, two T-lineage ALL/NHL cell lines </plain></SENT>
<SENT sid="3" pm="."><plain>CPI-2-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in LYN-deficient and BTK-deficient subclones of the DT-40 <z:hpo ids='HP_0002665'>lymphoma</z:hpo> B cell line as effectively as it did in <z:mp ids='MP_0002169'>wild-type</z:mp> DT-40 cells </plain></SENT>
<SENT sid="4" pm="."><plain>Thus, CPI-2-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> is not dependent on the protein tyrosine kinases LYN or BTK </plain></SENT>
<SENT sid="5" pm="."><plain>Notably, caspase inhibitor I effectively inhibited CPI-2-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, suggesting that the inhibition of a CPI-2-susceptible protease results in caspase activation, leading to <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in ALL/NHL cells </plain></SENT>
<SENT sid="6" pm="."><plain>Unlike the high calpain-expressing ALL/NHL cell lines, myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> cell lines <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>-60/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, K562/<z:mp ids='MP_0005481'>CML</z:mp>, and U937/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMML</z:e>, or <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> cell lines BT-20/<z:hpo ids='HP_0003002'>breast cancer</z:hpo>, PC-3/<z:hpo ids='HP_0012125'>prostate cancer</z:hpo>, U373/<z:hpo ids='HP_0100843'>glioblastoma</z:hpo>, and HeLa/epitheloid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, were not susceptible to the cytotoxicity of CPI-2 </plain></SENT>
<SENT sid="7" pm="."><plain>Taken together, our results identify calpain as a new molecular target for the treatment of ALL and NHL </plain></SENT>
<SENT sid="8" pm="."><plain>CPI-2 and its analogues represent a promising new class of antileukemia/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> agents that deserves further development </plain></SENT>
</text></document>